These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1655 related articles for article (PubMed ID: 8306245)

  • 1. A general extracorporeal immunoadsorption method to increase tumor-to-tissue ratio.
    Strand SE; Norrgren K; Garkavij M; Lindgren L; Nilsson R; Sjogren HO; Tennvall J
    Cancer; 1994 Feb; 73(3 Suppl):1033-7. PubMed ID: 8306245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving radioimmonotargeting of tumors. Variation in the amount of L6 MAb administered, combined with an immunoadsorption system (ECIA).
    Garkavij M; Tennvall J; Strand SE; Norrgren K; Nilsson R; Lindgren L; Sjögren HO
    Acta Oncol; 1993; 32(7-8):853-9. PubMed ID: 8305236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A general, extracorporeal immunoadsorption method to increase the tumor-to-normal tissue ratio in radioimmunoimaging and radioimmunotherapy.
    Norrgren K; Strand SE; Nilsson R; Lindgren L; Sjögren HO
    J Nucl Med; 1993 Mar; 34(3):448-54. PubMed ID: 8441037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving tumor-to-normal-tissue ratios of antibodies by extracorporeal immunoadsorption based on the avidin-biotin concept: development of a new treatment strategy applied to monoclonal antibodies murine L6 and chimeric BR96.
    Tennvall J; Garkavij M; Chen J; Sjögren HO; Strand SE
    Cancer; 1997 Dec; 80(12 Suppl):2411-8. PubMed ID: 9406691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracorporeal immunoadsorption compared to avidin chase: enhancement of tumor-to-normal tissue ratio for biotinylated rhenium-188-chimeric BR96.
    Chen JQ; Strand SE; Tennvall J; Lindgren L; Hindorf C; Sjögren HO
    J Nucl Med; 1997 Dec; 38(12):1934-9. PubMed ID: 9430473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracorporeal immunoadsorption from whole blood based on the avidin-biotin concept. Evaluation of a new method.
    Garkavij M; Tennvall J; Strand SE; Nilsson R; Lindgren L; Chen J; Isaksson M; Eriksson H; Sjögren H
    Acta Oncol; 1996; 35(3):309-12. PubMed ID: 8679261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced radioimmunotargeting of 125I-labeled L6-biotin monoclonal antibody (MAb) by combining preload of cold L6 MAb and subsequent immunoadsorption in rats.
    Garkavij M; Tennvall J; Strand SE; Norrgren K; Lindgren L; Nilsson R; Sjögren HO
    Cancer Res; 1995 Dec; 55(23 Suppl):5874s-5880s. PubMed ID: 7493363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 125I- and (111)In-labeled monoclonal antibody BR96 for tumor targeting in combination with extracorporeal immunoadsorption.
    Garkavij M; Tennvall J; Ohlsson T; Lindgren L; Hindorf C; Sjögren HO; Strand SE
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3059s-3064s. PubMed ID: 10541344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracorporeal whole-blood immunoadsorption enhances radioimmunotargeting of iodine-125-labeled BR96-biotin monoclonal antibody.
    Garkavij M; Tennvall J; Strand SE; Sjögren HO; JianQing C; Nilsson R; Isaksson M
    J Nucl Med; 1997 Jun; 38(6):895-901. PubMed ID: 9189138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma.
    Li GP; Zhang H; Zhu CM; Zhang J; Jiang XF
    World J Gastroenterol; 2005 Oct; 11(40):6288-94. PubMed ID: 16419157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving radioimmunotargeting of tumors: the impact of preloading unlabeled L6 monoclonal antibody on the biodistribution of 125I-L6 in rats.
    Garkavij M; Tennvall J; Strand SE; Norrgren K; Nilsson R; Sjögren HO
    J Nucl Biol Med (1991); 1994 Dec; 38(4):594-600. PubMed ID: 7786923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeating the avidin "chase" markedly improved the biodistribution of radiolabelled biotinylated antibodies and promoted the excretion of additional background radioactivity.
    Kobayashi H; Sakahara H; Endo K; Yao ZS; Toyama S; Konishi J
    Eur J Cancer; 1995 Sep; 31A(10):1689-96. PubMed ID: 7488426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of extracorporeal immunoadsorption to reduce circulating blood radioactivity after intraperitoneal administration of indium-111-HMFG1-biotin.
    Wang Z; Garkavij M; Tennvall JG; Ohlsson T; Strand SE; Sjögren HO
    Cancer; 2002 Feb; 94(4 Suppl):1287-92. PubMed ID: 11877758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avidin chase reduces side effects of radioimmunotherapy in nude mice bearing human colon carcinoma.
    Li GP; Wang YX; Huang K; Zhang H; Zhang CF
    World J Gastroenterol; 2005 Apr; 11(13):1917-21. PubMed ID: 15800980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft.
    Stein R; Chen S; Haim S; Goldenberg DM
    Cancer; 1997 Dec; 80(12 Suppl):2636-41. PubMed ID: 9406718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a "chase" without decreased accumulation in the target tumor.
    Kobayashi H; Sakahara H; Hosono M; Yao ZS; Toyama S; Endo K; Konishi J
    J Nucl Med; 1994 Oct; 35(10):1677-84. PubMed ID: 7931671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biotinylation, pharmacokinetics, and extracorporeal adsorption of humanized MAb 111In-MN14 using an avidin-affinity column in rats.
    Wang Z; Garkavij M; Ohlsson T; Strand SE; Sjögren HO; Tennvall J
    Cancer Biother Radiopharm; 2003 Jun; 18(3):365-75. PubMed ID: 12954123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small-cell carcinoma of the lung.
    Stein R; Goldenberg DM; Thorpe SR; Mattes MJ
    J Nucl Med; 1997 Mar; 38(3):391-5. PubMed ID: 9074526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma.
    Lindén O; Kurkus J; Garkavij M; Cavallin-Ståhl E; Ljungberg M; Nilsson R; Ohlsson T; Sandberg B; Strand SE; Tennvall J
    Cancer Biother Radiopharm; 2005 Aug; 20(4):457-66. PubMed ID: 16114994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of 111In- and 125I-labeled monoclonal antibody 17-1A in mice bearing xenografts of human pancreatic carcinoma HuP-T4.
    Maeda M; Shoji M; Kawagoshi T; Futatsuya R; Honda T; Brady LW
    Cancer; 1994 Feb; 73(3 Suppl):800-7. PubMed ID: 8306263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 83.